Patents

 

  • Molecularly cloned diagnostic product and method of use. United States Patent 4,855,224 (Berman and Lasky, August 8, 1989) Assignee: Genentech, Inc.
  • Method for isolation of unclipped HIV envelope protein. United States Patent 5,674,984 (Berman et al., October 7, 1997) Assignee: Genentech, Inc.
  • Method for making unclipped HIV envelope protein. United States Patent 5,849,533 (Berman et al., December 15, 1998) Assignee: Genentech, Inc.
  • Vaccine based on membrane bound proteins and process for making them. United States Patent 5,851,533 (Berman and Lasky, December 22, 1998) Assignee: Genentech, Inc.
  • Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use. United States Patent 5,853,978(Berman et al., December 29, 1998) Assignee: Genentech, Inc.
  • HIV envelope polypeptides. United States Patent 5,864,027 (Berman and Nakamura, January 26, 1999) Assignee: Genentech, Inc.
  • HIV envelope polypeptides. United States Patent 6,042,836 (Berman and Nakamura, March 28, 2000) Assignee: Genentech, Inc.
  • HIV envelope polypeptides and vaccine. United States Patent 6,090,392 (Berman, July 18, 2000) Assignee: Genentech, Inc.
  • HIV envelope polypeptides. United States Patent 6,331,404 (Berman and Nakamura, December 18, 2001) Assignee: Genentech, Inc.
  • Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use. United States Patent 6,534,285 (Berman et al., March 18, 2003) Assignee: Genentech, Inc.
  • HIV envelope polypeptides and immunogenic composition. United States Patent 6,585,979 (Berman, July 1, 2003) Assignee: Genentech, Inc.
  • Protein secretion. United States Patent 6,693,181 (Ashkenazi et al., February 17, 2004) Assignee: Genentech, Inc.
  • HIV envelope polypeptides. United States Patent 6,806,055 (Berman and Nakamura, October 19, 2004) Assignee: Genentech, Inc.
  • HIV env antibodies. United States Patent 7,041,293 (Berman et al., May 9, 2006) Assignee: Genentech, Inc.
  • HIV envelope polynucleotides and immunogenic composition. United States Patent 7,071,322 (Berman, July 4, 2006) Assignee: Genentech Inc.
  • HIV-1 envelope glycoproteins having unusual disulfide structure (patent pending). United States Patent Application 20/866,527 filed June 10, 2004.  (Berman and Jobes) Assignee: VaxGen, Inc.
  • Use of intrapatient sequence variation to identify epitopes of HIV envelope glycoprotein recognized by broadly neutralizing antibodies. United States provisional patent application (Berman) Assignee: University of California Regents.
  • Selection of HIV vaccine antigens by use of intrapatient sequence variation to identify mutations in the HIV envelope glycoprotein that affect the binding of broadly neutralizing antibodies. (Berman et al.) filed as international application PCT/US09/59583 on October 5, 2009. Assignee: University of California Regents.
  • Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating HIV. United States patent application (Berman et al.) filed as 61253858 on October 22, 2009. Assignee: University of California Regents.
  • Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in HIV-1 gp120. United States patent application (Berman et al.) filed as 61/258,833 on November 6, 2009. Assignee: University of California Regents.